Conexeu Sciences Inc. (NASDAQ:CNXU) ("Conexeu" or the "Company"), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today announced a human collagen program for regenerative aesthetics, starting with the production of its first pilot batch of human type I collagen.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.